NewAmsterdam Pharma
NAMS
137 hedge funds and large institutions have $3.42B invested in NewAmsterdam Pharma in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 40 reducing their positions, and 15 closing their positions.
62% more capital invested
Capital invested by funds: $2.11B → $3.42B (+$1.32B)
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
20% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 40
5% more funds holding
Funds holding: 131 → 137 (+6)
3.41% more ownership
Funds ownership: 103.65% → 107.06% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
96% less call options, than puts
Call options by funds: $2.48M | Put options by funds: $69.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$87M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$34.4M |
| 3 |
Jennison Associates
New York
|
+$30M |
| 4 |
DFO
Duquesne Family Office
New York
|
+$26.2M |
| 5 |
Morgan Stanley
New York
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIS
FCPM III Services
Naarden,
Netherlands
|
-$34M |
| 2 |
DM
Deerfield Management
New York
|
-$20.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$17.7M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$12.6M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$12.1M |
NAMS Hedge Fund Activity: Q3 2025 in Review
137 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q3 2025, worth a combined $3.42B — up 62% from $2.11B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NAMS positions and 15 closed out — a net gain of 6 holders — while 48 added to existing stakes and 40 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $87M. The largest seller was FCPM III Services, cutting an estimated $34M.
- 137 institutional investors held NewAmsterdam Pharma (NAMS) as of Q3 2025, up from 131 in Q2 2025.
- Funds reported $3.42B of NewAmsterdam Pharma stock for Q3 2025, up 62% quarter-over-quarter.
- 21 funds opened new NewAmsterdam Pharma positions in Q3 2025 and 15 closed out, a net change of +6 holders.
- The largest NewAmsterdam Pharma buyer in Q3 2025 was Fidelity Investments, an estimated $87M added.
- The largest NewAmsterdam Pharma seller in Q3 2025 was FCPM III Services, an estimated $34M sold.
Based on aggregated 13F filings for Q3 2025.